Archemix Hemophilia Assets Bought By Baxter

Archemix, a Cambridge, MA-based biotech developing aptamer drugs for the treatment of chronic and acute diseases, has sold its assets in the hemophilia space to Baxter International, according to an announcement today. Baxter (NYSE: BAX) will pay Archemix $30 million upfront and up to $285 million in milestone payments in an exclusive license agreement for the assets, which include ARC19499, a hemophilia treatment in a Phase 1 clinical trial in the U.K. The deal is expected to close this year.

Trending on Xconomy